Sector News

Integra LifeSciences to spin off spine unit

November 5, 2014
Life sciences
(Reuters) – Surgical devices and orthopedic care company Integra LifeSciences Holdings Corp said it would spin off its spine unit in an attempt to streamline its operations.
 
The company will continue to produce specialty surgical products and orthopedics and tissue therapies, while the new company will be called SeaSpine.
 
The company, which expects to take a one-time charge on the spin-off, revised its full-year profit forecast to 81-99 cents a share, down from its earlier forecast of $1.06 to $1.24 per share.
 
Piper Jaffray & Co. served as the company’s financial advisor, while Latham & Watkins LLP was the legal counsel in connection with the proposed spin-off transaction.
 
(Reporting by Vidya L Nathan in Bangalore; Editing by Joyjeet Das)

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach